Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
These 5 ASX 200 shares were last week's biggest gainers
Share Market News
ASX 200 Weekly Wrap: ASX bulls roar with 4th straight week of gains
Share Gainers
These were the best performing ASX 200 shares last week
⏸️ TMF AMP
ASX 200 update: Big four banks tumble and Transurban's traffic evaporates
⏸️ TMF AMP
ASX 200 jumps 7% on Monday
Share Market News
These ASX shares were last week's biggest gainers
Share Market News
Insiders have been buying Kogan and these ASX shares this week
Share Market News
Why Mayne Pharma, Collins Foods, and Perenti are tumbling lower today
Share Fallers
Why Altium and these other ASX shares fell 20% in February
Share Market News
Crown and these ASX 200 shares just crashed to multi-year lows
Share Market News
ALL ORDINARIES finishes lower Friday: 8 ASX shares you missed
Share Fallers
Why Ardent Leisure, BWX, Mayne Pharma, & New Hope are sinking lower
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
